StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Trading Down 2.7 %

NASDAQ:NERV opened at $2.17 on Monday. The company has a 50-day moving average of $2.24 and a 200-day moving average of $2.62. The firm has a market cap of $15.17 million, a price-to-earnings ratio of -4.93 and a beta of 0.11. Minerva Neurosciences has a twelve month low of $2.06 and a twelve month high of $13.49.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.